BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Daily injections of vosoritide sped up growth rates for children with the most common form of dwarfism.

BioMarin to Present Results of Successful Achondroplasia Study

SAN RAFAEL, Calif., Sept. 11, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting

Cameco

Illumina

PFSweb

Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.

These 4 Stocks Could Be Toxic for Your Portfolio

Avis Budget Group

SmileDirectClub

Baker Hughes Co

Invesco

QuidelOrtho Corp

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys Last Week: Avis Budget, SmileDirectClub And More

BioMarin Pharmaceutical (BMRN) closed at $76 in the latest trading session, marking a +0.21% move from the prior day.

BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should Know

After a 30% drop in August this year, at the current price of around $77 per share we believe BioMarin’s stock, a relatively small pharmaceutical company, looks oversold and it can offer significant upside. BMRN stock has moved from $120 to $78 in the month of August compared to the S&P which.

Is BioMarin Stock Oversold At $77?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

BioMarin (BMRN) Down 34.9% Since Last Earnings Report: Can It Rebound?

BioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia Trials

Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.

Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?

BioMarin has seen a big setback in approval of its hemophilia A candidate, although it might just be a delay.

BioMarin Pharmaceutical: Appealing After A Pipeline Setback

BioMarin Pharmaceuticals: Appealing After A Pipeline Setback

Getting new one-time treatments to patients who need them isn't getting any easier.

Is Biomarin's Disaster Bad News for Your Gene Therapy Stocks?

BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.

BioMarin Down on CRL From FDA for Hemophilia A Candidate

NVIDIA

Target

Lowe's

Visa

Nvidia, BioMarin, Visa, Lowe's and Target were our top stock trades. That said, let's look at what the charts are telling us now.

5 Top Stock Trades for Thursday: TGT, LOW, V, BMRN, NVDA

Momenta Pharmaceuticals

The Fed spoiled the party for the stock market.

Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite Directions

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares were plunging Wednesday after a negative outcome for a binary event.

BioMarin Shares Slammed After Hemophilia A Gene Therapy Stumbles At FDA

The biotech is going to have to wait awhile to get its hemophilia A treatment approved by the FDA.

Here's Why BioMarin Pharmaceutical Plummeted Today

It's bad news for hemophilia A sufferers in the U.S., and for the company's shareholders.

FDA Rejects BioMarin's Hemophilia Gene Therapy

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock was crushed on Wednesday after the company announced that the U.S.

What This FDA Response Means for BioMarin’s Gene Therapy for Hemophilia

Shares of BioMarin Pharmaceutical Inc. BMRN, -30.76% tumbled 27.6% in trading on Wednesday after the company said it had received a complete response letter from the Food and Drug Administration for its experimental hemophilia A treatment.

BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drug

BioMarin Pharmaceutical on Wednesday said the U.S. Food and Drug Administration wants more data on its hemophilia A gene therapy.

BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock Plunges

FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301

BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.

BioMarin's MAA for Dwarfism Candidate Gets EMA Validation

Is  (BMRN) Outperforming Other Medical Stocks This Year?

News for BioMarin Pharmaceutical Stock (BMRN)